SUZHOU, China, March 17, 2026 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and VEGFR2, for the treatment of advanced malignant solid tumors. JSKN027 is the company’s fifth ADC candidate entering clinical development, as well as the world’s first PD-L1/ VEGFR2 bispecific ADC to advance into clinical trials.

As the global burden of malignant tumors continues to rise, there is an urgent clinical need for more effective and innovative therapies applicable across various tumor types. PD-L1 is a key molecule in regulating immune responses, and VEGFR2 is a core signaling hub in tumor angiogenesis. Within the immunosuppressive microenvironment of various solid tumors, the VEGF/VEGFR signaling pathway and the PD-1/PD-L1 axis exhibit a synergistic interplay, collectively driving immune evasion and providing a new strategy for dual-target therapy. JSKN027 is an innovative bispecific ADC designed based on this synergistic mechanism. By leveraging glycan-specific conjugation technology, it precisely links its cleavable linker and topoisomerase I inhibitor payload to the antibody’s Fc region. This design confers multiple mechanisms of action, including targeted chemotherapy, anti-angiogenesis and immunotherapy. It is expected to synergistically enhance antitumor efficacy and overcome therapeutic resistance, offering a promising treatment strategy across solid tumors.

JSKN027-101 is an open-label, multi-center, Phase I clinical study, including dose-escalation and dose-expansion phases. This study aims to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD), and antitumor activity of JSKN027 in patients with advanced malignant solid tumors, and determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).

About JSKN027

JSKN027 is a first-in-class bispecific ADC designed to co-engage PD-L1 and VEGFR2. By leveraging glycan-specific conjugation technology, it precisely links its cleavable linker and topoisomerase I inhibitor payload to the antibody’s Fc region – maintaining a strong safety profile while unlocking potent anti-tumor activity.

JSKN027’s efficacy stems from a unique three-fold synergistic mechanism. Beyond the standard ADC effects of targeted cell killing and bystander activity, it also inhibits tumor angiogenesis by blocking VEGF/VEGFR2 signaling and reverses immune suppression by disrupting the PD-1/PD-L1 checkpoint. This integrated attack enhances overall anti-tumor power and is anticipated to help overcome therapeutic resistance. As a result, JSKN027 is poised to offer a novel and robust treatment avenue for patients across multiple solid tumor types. The Phase I clinical study of JSKN027 in patients with advanced malignant solid tumors has been conducted in China.

About Alphamab Oncology

Alphamab Oncology (Stock Code: 9966.HK) is an innovative biopharmaceutical company focused on oncology. Leveraging proprietary platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.

One product has received market approval: Envafolimab (KN035, brand name: 恩维达^®), the world’s first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Five bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, enabling patients to achieve long-term, high-quality survival and delivering China-innovated cancer therapies to benefit patients worldwide.

BEIJING, March 17, 2026 /PRNewswire/ — A special video series produced by the China Daily Opinion Channel during the annual two sessions brings together perspectives from five national political advisers on priorities for the 15th Five-Year Plan (2026-30) period.

Featuring interviews with five members of the 14th National Committee of the Chinese People’s Political Consultative Conference — Huang Qunhui, Jiang Ying, Dai Bin, Feng Li and Xu Jiuping — the series examines how China can advance high-quality growth, strengthen cultural vitality and cultivate future-ready talent.

Huang Qunhui, a researcher at the Institute of Economics, Chinese Academy of Social Sciences, emphasizes the role of developing “new quality productive forces” in supporting China’s modernization. He says China can draw on its institutional strengths, large market, industrial base and talent pool to upgrade traditional industries, expand domestic demand and proactively plan for emerging and future industries.

Jiang Ying, chair of Deloitte China, addresses the problem of excessive competition — often described as “involution”. She argues that the core issue is not competition itself, but that value is not fully reflected in pricing and market rules. During the next plan period, she calls for competition mechanisms guided by long-term value so that quality products, advanced technology and strong services can command fair prices. She also highlights sectors such as artificial intelligence and the low-altitude economy as key areas for breakthrough.

Dai Bin, president of the China Tourism Academy, discusses the recovery of inbound tourism and the popularity of “China Travel”. While facilitation has helped more visitors enter China, he notes that success depends on improving the experience after arrival. That includes developing new tourism resources, better mobilizing market players such as travel firms, and upgrading public services to encourage longer stays and deeper exploration.

Feng Li, president of the China National Opera & Dance Drama Theater, reflects on the arts as a source of cultural confidence. She stresses a people-centered approach and the importance of responding to the times. Citing the classic opera The White-Haired Girl, she says enduring works resonate because they tap universal emotions and renew themselves through sustained practice.

Xu Jiuping, a distinguished professor at Sichuan University, focuses on education in the AI era. While AI is reshaping industries and learning, he stresses that education must reinforce fundamental disciplines, language ability and critical thinking. Combining technological empowerment with humanistic knowledge, he says, is essential for nurturing innovative talent for the decade ahead.

https://www.chinadaily.com.cn/a/202603/12/WS69b79715a310d6866eb3e0ce.html

HONG KONG, March 17, 2026 /PRNewswire/ — At the NVIDIA GTC Conference held on March 16, NVIDIA announced a deep integration between its Omniverse NuRec and 51WORLD’s SimOne. Leveraging neural rendering technology, this collaboration successfully solves the industry pain point where real-world collected scenario data is non-interactive. This breakthrough will accelerate the development of reasoning-based autonomous driving systems, such as VLA and World Models, empowering global L4 automotive partners.

It is reported that 51WORLD has achieved a 53.5% market share in China’s L3+ simulation sector. This partnership will further solidify 51WORLD’s core position in the global Physical AI arena.

HONG KONG, March 17, 2026 /PRNewswire/ — At the NVIDIA GTC Conference held on March 16, NVIDIA announced a deep integration between its Omniverse NuRec and 51WORLD’s SimOne. Leveraging neural rendering technology, this collaboration successfully solves the industry pain point where real-world collected scenario data is non-interactive. This breakthrough will accelerate the development of reasoning-based autonomous driving systems, such as VLA and World Models, empowering global L4 automotive partners.

It is reported that 51WORLD has achieved a 53.5% market share in China’s L3+ simulation sector. This partnership will further solidify 51WORLD’s core position in the global Physical AI arena.

SAN JOSE, Calif., March 17, 2026 /PRNewswire/ — At the NVIDIA GTC Conference held on March 16, NVIDIA announced a deep integration between its Omniverse NuRec and 51WORLD’s SimOne. Leveraging neural rendering technology, this collaboration successfully solves the industry pain point where real-world collected scenario data is non-interactive. This breakthrough will accelerate the development of reasoning-based autonomous driving systems, such as VLA and World Models, empowering global L4 automotive partners.

It is reported that 51WORLD has achieved a 53.5% market share in China’s L3+ simulation sector. This partnership will further solidify 51WORLD’s core position in the global Physical AI arena.

SAN JOSE, Calif., March 17, 2026 /PRNewswire/ — At the NVIDIA GTC Conference held on March 16, NVIDIA announced a deep integration between its Omniverse NuRec and 51WORLD’s SimOne. Leveraging neural rendering technology, this collaboration successfully solves the industry pain point where real-world collected scenario data is non-interactive. This breakthrough will accelerate the development of reasoning-based autonomous driving systems, such as VLA and World Models, empowering global L4 automotive partners.

It is reported that 51WORLD has achieved a 53.5% market share in China’s L3+ simulation sector. This partnership will further solidify 51WORLD’s core position in the global Physical AI arena.

SINGAPORE, March 17, 2026 /PRNewswire/ — Dr Cho Li Wei, leading LW Cho Endocrine Clinic, is marking 23 years in endocrinology and 27 years in clinical practice, with a continued focus on bridging language gaps in specialist medical care. The clinic serves patients across conditions including diabetes, thyroid disorders, polycystic ovary syndrome (PCOS), osteoporosis, menstrual disorders, and pituitary disorders. Consultations are conducted in English, Mandarin, Cantonese, Hakka, Hokkien, and Bahasa.

The clinic’s multilingual capability addresses a practical challenge that many endocrinology patients face: the difficulty of communicating nuanced symptoms and understanding long-term treatment plans in a second language. By consulting patients directly in their preferred language, the clinic aims to reduce miscommunication during diagnosis and follow-up, particularly for older patients and those from non-English-speaking backgrounds. This is especially relevant for managing chronic conditions such as diabetes, where patient understanding is closely tied to treatment outcomes. The ability to converse in Chinese, including the various dialects such as Cantonese, Hakka, and Hokkien, as well as in Bahasa is particularly relevant in Singapore, where a segment of the elderly population remains more comfortable in their mother tongue than in English.

LW Cho Endocrine Clinic covers a broad scope of endocrine services, including polycystic ovary syndrome treatment, thyroid management, and osteoporosis treatment in Singapore. Dr Cho Li Wei, who holds a medical degree from the University of Glasgow and a doctorate and CCT (specialist accreditation) from the United Kingdom, also manages adrenal and pituitary disorders, endocrine hypertension, hypogonadism, reproductive endocrinology, and weight-related metabolic conditions. She has a subspecialty interest in PCOS and insulin resistance syndrome and has published extensively in these areas, with around 30 publications and more than 700 citations.

Having served 23 years in endocrinology and 27 years in clinical practice, Dr Cho Li Wei has shaped her approach around continuity of care and accessible communication. As LW Cho Endocrine Clinic marks this milestone, the practice continues supporting individuals living with endocrine conditions through specialised care grounded in long-term patient relationships.

For more information on LW Cho Endocrine Clinic and its range of services, please visit https://choendocrine.com.sg/.